In myeloproliferative neoplasms the JAK-STAT signaling pathway can be inhibited with the JAK1/JAK2 inhibitor ruxolitinib and in rheumatoid arthritis with less selective JAK inhibitors such as tofacitinib and baricitinib [31]. This evidence concerns the gene SOAT1 and rheumatoid arthritis.